LYSAVAX-CoV-2

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameLYSAVAX-CoV-2

Drug Alias NameSARS-CoV-2 vaccine (Alloplexo Biotherapeutics)

ClassificationBiologics > Protein drugs > Recombinant proteinVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine

Mechanisms of ActionImmunomodulators

TargetsNot applicable

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAlloplex Biotherapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAlloplex Biotherapeutics Inc

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A